Beone Medicines LTD. income statement & cash flow
In the fiscal year ended Dec 31, 2025, Beone Medicines LTD. reported net income of $286.93M on revenue of $5.34B. Operating cash flow was $1.13B and capital expenditures were $185.84M, leaving $941.74M of free cash flow (operating cash flow minus capital expenditures).
Income statement and cash flow summary
| Fiscal year ended | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.07M | $238.39M | $198.22M | $428.21M | $308.87M | $1.18B | $1.42B | $2.46B | $3.81B | $5.34B |
| Gross profit | — | — | — | — | — | $1.01B | $1.13B | $2.08B | $3.22B | $4.67B |
| Operating income | −$117.06M | −$98.46M | −$705.77M | −$959.89M | −$1.66B | −$1.44B | −$1.79B | −$1.21B | −$568.20M | $447.14M |
| Net income | −$119.22M | −$93.11M | −$673.77M | −$948.63M | −$1.62B | −$1.46B | −$2.00B | −$881.71M | −$644.79M | $286.93M |
| Diluted EPS | — | — | — | −$1.22 | −$1.50 | −$1.21 | −$1.49 | −$0.65 | −$0.47 | $0.19 |
| Operating cash flow | −$89.51M | $12.75M | −$547.72M | −$750.27M | −$1.28B | −$1.30B | −$1.50B | −$1.16B | −$140.63M | $1.13B |
| Capital expenditures | $23.50M | $46.37M | $70.28M | $89.61M | $117.51M | $262.94M | $325.43M | $561.90M | $492.66M | $185.84M |
| Reported in | 10-K 2019 | 10-K 2020 | 10-K 2021 | 10-K 2022 | 10-K 2023 | 10-K 2024 | 10-K 2025 | 10-K 2026 | 10-K 2026 | 10-K 2026 |
Margins
Each figure divided by revenue for the same fiscal year.
| Fiscal year ended | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| Dec 2025 | 87.5% | 8.4% | 5.4% |
| Dec 2024 | 84.4% | -14.9% | -16.9% |
| Dec 2023 | 84.5% | -49.1% | -35.9% |
| Dec 2022 | 79.8% | -126.4% | -141.5% |
| Dec 2021 | 86.0% | -122.3% | -123.9% |
Source: SEC EDGAR XBRL company facts for CIK 1651308 (raw data). Most recent filing in this dataset: 10-Q filed Aug 5, 2026. SEC data file dated Nov 3, 2026; page built Nov 5, 2026. Figures are as most recently reported, including restatements. How we select figures.